With 93 Crohn’s Disease (CD) and 168 Ulcerative Colitis (UC) Phase I-III industry-sponsored studies planned and open to enrollment, there is a significant focus on research into new therapies for inflammatory bowel disease (IBD)1. Remission is the main aim of IBD therapy, but IBD studies often face challenges with minimizing …
![](https://ddblog.labcorp.com/wp-content/uploads/2020/01/IBD-Covance.png)